CED Cannabis Science Digest: 3 Mental Health, Prenatal, and Oncology Caution Signals
This digest highlights 2026 cannabis prenatal safety signals focusing on mental health risks, prenatal placental evidence, and oncology pilot trial insights. These signals guide clinical caution without overstating treatment claims. They sharpen…
Cannabis Science Full Report: What a Five-Year Low Back Pain Cannabis Cohort Can and Cannot Tell Us
A five-year medical-cannabis cohort study in chronic low back pain reported large improvements, but its uncontrolled design requires careful interpretation.
CED Cannabis Science Digest: Oncology, Prenatal, and Veterinary CBD Signals
This digest highlights oncology cannabis treatment adherence and three verified cannabis science signals. It covers prenatal cannabis research methods and veterinary cannabidiol oncology review. These signals provide valuable clinical insights for…
CED Cannabis Science Digest: 3 Brain and Road-Safety Signals Worth Watching
This digest highlights three verified brain and road-safety cannabis signals from 2026 research. It covers THC-positive roadside motorcyclists, MAGL withdrawal biology, and age-dependent CBD effects in epilepsy models. These signals sharpen counseling…
Cannabis and Tourette Tics: Reading the Adult Meta-Analysis Carefully
A 2026 systematic review and meta-analysis reported lower tic and premonitory-urge scores with cannabis-based medicines in adult Tourette studies. The result is promising, but it should be read as a cautious adult evidence signal, not as a universal…
Monlunabant for Diabetic Kidney Disease: Why a Negative CB1 Trial Matters
A phase 2 randomized trial of monlunabant, a second-generation CB1 inverse agonist, did not establish proof of concept in diabetic kidney disease. The result is important because negative trials help separate cannabinoid-pathway promise from clinical…
Cannabis Edibles, Alcohol, and Driving: What the JAMA Trial Shows
A JAMA Network Open crossover trial found that cannabis edibles combined with alcohol worsened simulated driving and subjective intoxication more than either substance alone. The study also shows why common field-sobriety signals can miss meaningful…
High-Dose CBD Significantly Reduced Neuropathic Pain in Spinal Cord Injury: What a New RCT Reveals
A new randomized controlled trial shows high-dose CBD neuropathic pain spinal cord injury treatment significantly reduces chronic neuropathic pain intensity. This placebo-controlled study found that oral CBD up to 800 mg/day led to meaningful pain relief…
CED Cannabis Science Digest: Withdrawal, Sleep, and Pediatric Signals
This digest highlights cannabis withdrawal symptom management alongside pediatric exposure and adolescent sleep risk signals. It provides evidence-aware insights for clinicians and caregivers. These public-health signals inform safer counseling and…
CBN and CBD May Help Sleep. THC Does Not – And Now There Are Dosing Numbers.
A 2026 cannabis for insomnia meta-analysis finds CBD (50-300 mg) and CBN (20-100 mg) reduce sleep disturbance in adults with insomnia. THC formulations failed to outperform placebo and carried a higher adverse-effect burden. This evidence review covers…